Foundation — a swamplink research property
Iteration counts are not disclosed by anyone in this corpus. What is public is what has to be proven before a formula can ship — this page sources that instead of guessing the rest.
How many prototypes, how many failed batches, how many months a specific formula took — no manufacturer in this corpus discloses that, and it could not be found sourced anywhere else either. That number lives inside a company's R&D function and never reaches a filing, an annual report or a standard. Anything claiming a precise iteration count for the industry is not reporting a fact; it is guessing. This page does not guess.
What it does instead is answer a narrower, checkable question: what is a manufacturer legally required to prove about a formula's stability before that formula may ship, and how is that requirement structured. That's not the same question as "how many tries did it take" — but it is the part of development time that a regulator, not a marketing brief, actually controls, and it is the same reasoning MoCRA's own safety-substantiation duty rests on: a company must be able to show its work, even though the work itself stays private.
21 CFR 211.166 is the rule that actually binds these twelve products. Every product in this corpus carries an SPF claim, which makes it an OTC drug in the US — so this cGMP requirement, not general cosmetics practice, is what actually binds these twelve products.
Source: 21 CFR 211.166 — Stability testing — eCFR (Office of the Federal Register / GPO). Text as displayed 2026-08-19, current to amendments through 46 FR 56412 (17 Nov 1981); unchanged since.
The load-bearing clause is the one about accelerated data: a company can launch on a projected shelf life while real-time testing is still running, but only as a tentative date that must later be verified. That's the mechanism that lets a product with a two-year claimed shelf life ship well under two years after formulation is finalized, without skipping the real-time study — the real-time data just keeps running in the background after launch.
Guidelines on Annex I to Regulation (EC) No 1223/2009 — stability of the cosmetic product requires a documented stability assessment for every cosmetic product placed on the EU market, drug claim or not. The SCCS has recommended that 'relevant stability tests, adapted to the type of cosmetic product and its intended use, should be carried out.'
Source: 2013/674/EU, Annex, point 3.2.3 — legislation.gov.uk (mirror of Commission Implementing Decision 2013/674/EU). Adopted 25 November 2013, published in the Official Journal 26 November 2013; guidance on Annex I of Regulation (EC) No 1223/2009, unchanged since adoption.
The EU rule is broader than the US one in scope — it covers all twelve products in this corpus, not just the OTC-drug half of what those products' SPF claims trigger — and it is explicit about testing in the real market packaging rather than a neutral reference container, because packaging interactions are themselves a stability variable.
16% less than 12 months · 58% said 12–18 months · 26% more than 18 months
Cosmetics & Toiletries reader poll, 2023-10-02 — Cosmetics & Toiletries
A self-selected 1-click reader poll, not a methodology-disclosed survey — treated here as color, matching what the site's own issue tracker called this page, not as a sourced statistic on the order of the corpus figures elsewhere on this site.
It's included anyway because it's the only concept-to-launch timeline figure found with an attributable publisher and date — and because, read against the two stability rules above, the 12–18 month plurality is not surprising. A product claiming a multi-year shelf life needs months of accelerated data before it can even launch on a tentative date, and that requirement alone accounts for most of the low end of the range.